9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)

✍ Scribed by Leighl, N.; Reck, M.; de Haas, S.; Evers, S.; Delmar, P.; Manegold, C.; Scherer, S.

• Book ID: 122474692
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 49 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71885-3